Kailera Therapeutics has filed for an IPO, hoping to whet investor appetites with its pipeline of drug candidates for weight loss.
Sanofi on Saturday shared more mixed efficacy results from a Phase 3 atopic dermatitis program for its anti-OX40 ligand monoclonal antibody, further eroding Wall Street’s
A study has found that undiagnosed heart failure can be detected in people with high-risk diabetes using a simple, GP-led care pathway.
One of biotech’s best-funded startups plans to go public, as it seeks to take its obesity portfolio into a market crowded by Eli Lilly, Novo
Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.
Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844